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The optimal healthcare model for follow-up of allogeneic hematopoietic stem cell transplantation (HSCT)
recipients after day 100 is not clear. We previously demonstrated that longitudinal follow-up at the transplant
center using a multidisciplinary approach is associated with superior survival. Recent data suggest that
increased distance from the transplant center is associated with inferior survival. A dedicated long-term
transplant clinic (LTTC) was established in 2006 at our center. We hypothesized that geographic distance
would not be associated with inferior outcome if patients are followed in the LTTC. We studied 299
consecutive patients who underwent HSCT and established care in an LTTC. The median distance from the
transplant center was 118 miles (range, 1 to 1591). The 75th percentile (170 miles) was used as the cut-off to
analyze the impact of distance from the center on outcome (219 patients 75th percentile; 80 patients >75th
percentile). The 2 groups were balanced for pretransplant characteristics. In multivariate analyses adjusted
for donor type, Center for International Blood and Marrow Transplant Research risk, and transplant regimen
intensity, distance from transplant center did not impact outcome. Our study suggests that geographic dis-
tance from the transplant center is not associated with inferior outcome when follow-up care is delivered via
a dedicated LTTC incorporating well-coordinated multidisciplinary care.
Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation.INTRODUCTION infrastructure. In a recent discussion regarding long-term
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a potentially curative method of treating various
hematologic disorders [1]. With increasing focus on less toxic
preparation before transplantation and the continued im-
provement of prophylaxis against graft-versus-host-disease
(GVHD), the long-term survival after transplant is on the
rise [2]. As the indications for transplant increase and survival
trends improve, there is prospected to be up to half a million
long-term survivors of HSCT worldwide by 2020 [3]. Long-
term survivors after allogeneic HSCT require specialized
care because of the signiﬁcant and lasting effects of immune
system manipulation. Studies suggest that centers perform-
ing a higher number of transplants have better outcomes.
This has led to the concept of “centers of excellence,” and
patients are referred by third-party payers to these centers
irrespective of distance. Recent data suggest that long driving
times to transplant centers are associated with worse overall
survival (OS) [4]. Previous studies suggested that the patient’s
primary location of residence could be an independent risk
factor for OS [5].
There has been an insurgence of investigation in optimal
care models after transplantation to further improve out-
comes after HSCT [2,3,6,7]. The optimal healthcare model for
follow-up after day 100 post-HSCT is still not clear. Most
centers reintegrate patients into primary hematology clinics
with a few centers having dedicated long-term follow-updgments on page 56.
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was recommended, incorporating a proposed survivorship-
care plan and coordinated care between the transplant
center, primary care physicians, and other specialists [8].
The long-term transplant clinic (LTTC) was established
within the Vanderbilt transplant program in 2006 to provide
coordinated multidisciplinary care, with a focus on GVHD,
detection of early relapse, and prevention and management
of late effects of HSCT. We previously showed that longitu-
dinal follow-up in the LTTC is associatedwith superior OS [9].
We hypothesized that geographic distance would not be
associated with inferior outcome if patients are followed in a
dedicated follow-up clinic. In this study, we were able to
show that an organized approach to posteday-100 follow-up
helps to overcome the geographic barrier of distance from
the transplant center.METHODS
Patients
Since 2006, all adult patients beyond day 100 after an HSCT for hema-
tologic malignancies or nonmalignant disorders who were medically stable
for discharge from the transplant center were transitioned to the LTTC and
followed in a systematic manner. Between the establishment of the LTTC in
January 2006 and April 2012, 381 patients underwent allogeneic HSCTat our
center. Of these patients, 299 (78%) transitioned to the LTTC and were
included in this analysis.
Thirty-four patients (9.0%) who underwent transplant at other centers
transitioned their care to the LTTC for geographic, insurance, or social sup-
port reasons and subsequently transitioned at later time points beyond day
100. These patients were not included in the study population. Of the 381
patients, 46 (12%) were transplanted before 2006. Because these patients
could confound the analyses by lead time bias, they were excluded. Patients
who were unable to transition to the LTTC were excluded. Criteria for not
transitioning to the LTTC included requiring visits more frequently than
once a week, early relapse, early death, or medical instability. Thus, by Aprilcan Society for Blood and Marrow Transplantation.
Table 1
Patient Characteristics: Stratiﬁed by Distance from Transplant Center (Group
A, Distance 0 to 170 Miles; Group B, Distance > 170 Miles)
Variable Group A
(N ¼ 219)
Group B
(N ¼ 80)
Median distance, miles (range) 98 (1-170) 202 (172-1591)
Age, yr, median (range) 49 (19-70) 49 (22-67)
Recipient gender
Male (%) 114 (52) 45 (56)
Female (%) 105 (48) 35 (44)
Race
Caucasian (%) 204 (93) 66 (83)
Black (%) 5 (2) 7 (9)
Hispanic (%) 3 (1) 1 (1)
Other (%) 7 (4) 6 (7)
Karnofsky performance status
80 (%) 206 (94) 75 (94)
<80 (%) 13 (6) 5 (6)
LTTC transition
Before day 120 (%) 174 (80) 60 (75)
After day 120 (%) 45 (20) 20 (25)
Diagnosis
Acute leukemia (%) 102 (47) 42 (53)
Myeloid disorders (%) 47 (21) 14 (17)
Lymphoid disorders (%) 50 (23) 15 (19)
Other (MM, SAA) (%) 20 (9) 9 (11)
CIBMTR risk status
Low (%) 103 (47) 41 (51)
Intermediate (%) 62 (28) 18 (23)
High (%) 54 (25) 21 (26)
Donor type
Related (%) 112 (51) 44 (55)
Unrelated (%) 107 (49) 36 (45)
Transplant type
Ablative, related (%) 53 (24) 22 (28)
Ablative, unrelated (%) 47 (22) 16 (20)
Ablative, cord (%) 11 (5) 2 (2)
Nonablative, related (%) 57 (26) 23 (29)
Nonablative, unrelated (%) 42 (19) 14 (17)
Nonablative, cord (%) 9 (4) 3 (4)
Stem cell source
Peripheral blood (%) 167 (76) 60 (75)
Cord (%) 19 (9) 5 (6)
Bone marrow (%) 32 (14) 14 (18)
Bone marrow/peripheral blood (%) 1 (1) 1 (1)
Match grade
Related, HLA matched (%) 108 (49) 45 (56)
Unrelated, HLA identical (%) 84 (38) 26 (33)
Unrelated, HLA 1 mismatch (%) 6 (3) 1 (1)
Unrelated, HLA  2 mismatch (%) 21 (10) 8 (10)
ABO match
Match (%) 89 (41) 33 (41)
Mismatch (%) 130 (59) 47 (59)
Gender match
Match (%) 112 (51) 42 (53)
Mismatch (%) 107 (49) 38 (47)
CMV recipient and donor status
Recipient positive, donor positive (%) 76 (35) 28 (35)
Recipient positive, donor negative (%) 62 (28) 13 (16)
Recipient negative, donor positive (%) 35 (16) 11 (14)
Recipient negative, donor negative (%) 35 (16) 19 (24)
Unknown (%) 11 (5) 9 (11)
Regimen intensity
Ablative (%) 114 (52) 42 (52)
Nonablative (%) 105 (48) 38 (48)
Acute GVHD
None (%) 44 (20) 17 (21)
Grade I (%) 21 (10) 11 (14)
Grade II (%) 116 (53) 43 (54)
Grade III (%) 34 (15) 5 (6)
Grade IV (%) 3 (1) 3 (4)
Unknown (%) 1 (0.5) 1 (1)
Chronic GVHD
None (%) 86 (39) 26 (32)
Limited mild (%) 9 (4) 3 (4)
Limited moderate (%) 5 (2) 3 (4)
Extensive mild (%) 38 (18) 14 (18)
(continued)
Table 1
(continued)
Variable Group A
(N ¼ 219)
Group B
(N ¼ 80)
Extensive moderate (%) 40 (18) 15 (19)
Extensive severe (%) 30 (14) 13 (16)
Unknown (%) 11 (5) 6 (7)
Survival status
Alive (%) 168 (77) 66 (83)
Dead
Relapse (%) 36 (16) 9 (11)
NRM (%) 15 (7) 5 (6)
MM indicates multiple myeloma; SAA, severe aplastic anemia; NRM, non-
relapse mortality.
B.K. Ragon et al. / Biol Blood Marrow Transplant 20 (2014) 53e57542012, 299 patients transitioned to the LTTC andmet inclusion criteria for this
analysis. Vanderbilt University Institutional Review Board approved this
analysis.
Patients were followed in the LTTC on a monthly basis until 1 year post-
HSCT, every 2 months until month 16 (to coincide with vaccination at
months 12,14, and 16), and then every 3 to 4months until 2 years post-HSCT
or until off immunosuppression. Subsequent visits were every 6 to
12 months. Systematic follow-up for prevention, monitoring, and therapy of
late effects was undertaken [7]. Each patient was followed by a trained mid-
level provider and supervised by a physician. Three mid-level providers and
3 physicians participated in the LTTC. The total full time equivalentmid-level
provider assigned to the LTTC was 1.5. All patients were encouraged to
identify primary care providers either at Vanderbilt or in his or her home-
town. Dedicated consultants in cardiology, pulmonary, endocrinology, lipid
disorders, dermatology, and ophthalmology were identiﬁed as part of the
LTTC program. Many aspects of the care in LTTC were audited by the quality
assurance personnel assigned to the transplant program. Patients who could
not return to the center for follow-up as per protocol were contacted
through telephone. All patients were encouraged to use an electronic
communication system (myhealth@vanderbilt.com) embedded within the
electronic medical record system (StarPanel, Vanderbilt University). Refer-
ring oncologists and primary care physicians were updated through clinic
documentation on a periodic basis.
Data Source
Data obtained for analysis was gathered from the transplant data team
and the electronic medical record system. Patients transitioned to the LTTC
were added to electronic panels maintained within StarPanel by transplant
providers.
Distance Determination
Zip code of residence at the time of transplant for each patient was
obtained using the electronic medical record. We used Melissa Data [10], an
online provider of geocoding software, to determine the distance between
the medical center and the patient’s zip code of residence.
Variables of Interest
The following pretransplant covariates were obtained to assess any as-
sociation with the outcome of interest: age at the time of transplant, indi-
cation for transplant, disease risk status (low/intermediate versus high) as
deﬁned by the Center of International Blood and Marrow Transplant
Research (CIBMTR), Karnofsky performance status, recipient and donor
gender, recipient and donor ABO type, recipient and donor cytomegalovirus
serostatus, type of donor (related versus unrelated), and HLAmatching. Fully
matched donors had 8/8 or 10/10 HLA allele matches. Subsequently,
1 mismatch represented 7/8 or 9/10 matches. The transplant characteristics
included stem cell source, conditioning regimen, acute and chronic GVHD
severity, and cause of death (relapse versus nonrelapse causes).
Statistical Analysis
The primary outcome of interest in this study was OS. OS was calculated
from the time of transition to the LTTC to the date of last contact or date of
death. Cumulative incidence of nonrelapse mortality was calculated as
incidence of death from nonrelapse causes, with death due to relapse as a
competing risk.
Addressing the impact of geographic distance on OS when patients are
followed in a dedicated LTTC was the main reason for proceeding with this
study. Patients were separated into 2 groupswith 170miles representing the
75th percentile of distance distribution in the patients studied. The 75th
percentile was used as the cut-off to analyze the impact of distance from the
center on outcome. This was chosen as the distance of interest secondary to
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driving time of >160 minutes was associated with worsened OS. The dis-
tance of 170 miles, identiﬁed as the 75th percentile in this analysis, was
considered comparable with a driving time of at least 160 minutes. Group A
represents patients who lived less than 170miles from the transplant center,
and group B represents those patients who were greater than or equal to
170 miles from the transplant center.
Descriptive statistics, including median and range for continuous var-
iables and percentages and frequencies of categorical variables, were
calculated. Groups with nominal outcomes were compared using the chi-
square test; groups with continuous outcomes were compared using the
Wilcoxon rank sum test. OS was calculated from time of transition to the
LTTC until last contact or death. Kaplan-Meier survival curves were calcu-
lated for the group(s) and were compared using the log rank test [11].
Multivariable analyses were performed using Cox proportional hazard
regression. Analyses were performed using SPSS version 19 (IBM SPSS,
Armonk, New York) or R version 2.1.1 [12].
RESULTS
Patient Characteristics
Table 1 demonstrates the demographic information,
transplant characteristics, and transplant outcome variables
of the 299 patients included in this study. The characteristics
are described for each group. The population represented
had diagnoses that included acute leukemia (acute myelog-
enous leukemia, myelodysplastic syndrome/acute myeloge-
nous leukemia, acute lymphoblastic leukemia), myeloid
disorders (myelodysplastic syndrome, myeloproliferative
disorder, chronic myelogenous leukemia, myelodysplastic
syndrome/myeloproliferative disorder), lymphoid disorders
(non-Hodgkin lymphoma, chronic lymphocytic leukemia,
chronic lymphocytic leukemia/small lymphocytic lym-
phoma, other lymphoid, such as T cell prolymphocytic leu-
kemia), and others (myeloma and aplastic anemia). The
median distance from the transplant center was 118 miles
(range, 1 to 1591). The 75th percentile (170 miles) was used
as the cut-off to analyze the impact of distance from the
center on outcome (219 patients [73%]  75th percentile;
80 patients [27%] > 75th percentile).
Overall Survival
OS was calculated from transition to the LTTC until last
follow-up or death for the groups and is shown in Figure 1.
The median follow-up was 1.69 years (range, 0 to 6.3). Of the
299 patients, 65 dies (relapse, 45 [69%]; nonrelapse, 20
[31%]). There were no differences in the causes of death inFigure 1. OS stratiﬁed by distance from the transplant center. Survival
calculated from date of transition to the LTTC.the 2 groups (group A versus group B: relapse, 36 [71%]
versus 9 [64%]; nonrelapse, 15 [29%] versus 5 [36%]). Figure 2
shows the cumulative incidence of nonrelapse mortality. The
median survival was not reached. Two-year OS for the entire
patient population was 77.1% ( standard error, .029%). Two-
year OS for groups A and B were 76.3% ( standard error,
.034%) and 77.2% ( standard error, .058%), respectively
(P ¼ .29).Univariate and Multivariate Analysis
In univariate analyses, age (continuous variable), regimen
(ablative or other), donor (related or other), cytomegalovirus
serostatus, ABO type (match or mismatch), CIBMTR risk
status (low/intermediate versus high), and chronic GVHD did
not impact survival in the 2 groups. Acute GVHD was not
considered for analysis because all patients had to be alive at
time of transition to the LTTC.
Risk factors known to affect transplant were put in the
multivariate model. Using the Cox regression model of OS,
adjusted for donor type, CIBMTR risk status, regimen in-
tensity, and distance from transplant center (cut-off 75th
percentile), distance did not impact outcome. Multivariate
analyses of OS are shown in Table 2. Using the same cova-
riates, distance as a continuous variable did not impact sur-
vival (data not shown).DISCUSSION
Contrary to previous reports, we determined that
geographic distance from the transplant center is not associ-
ated with an inferior outcome when follow-up care is deliv-
ered via a dedicated long-term transplant follow-up clinic
incorporating well-orchestrated multidisciplinary care. The
LTTC team coordinated multidisciplinary care with dedicated
consultants in endocrinology, lipid, dermatology, pulmonary,
infectious disease, orthopedics, and ophthalmology. The LTTC
also encouraged each patient to have a local primary care
physician. All specialized correspondence was forwarded to
the patient’s primary care physician. With emphasis on
specialized care and dedicated follow-up, it can be inferred
that implementation of this healthcare model helps to elim-
inate the association of distance from transplant center and
worsened OS.Figure 2. Cumulative incidence of nonrelapse mortality stratiﬁed by distance
from the transplant center. Survival calculated from date of transition to the
LTTC.
Table 2
Multivariate Analysis (Cox Regression Model) for Survival
Variable Hazard
Ratio
95% Conﬁdence
Interval
P
Groups
Group A (reference) 1
Group B .702 .38-1.29 .251
Regimen intensity
Ablative (reference) 1
Other .688 .41-1.16 .162
CIBMTR risk status
Low/Intermediate
(reference)
1
High 1.316 .70-2.44 .403
Donor type
Related (reference) 1
Other 1.352 .82-2.21 .233
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Brigham and Women’s Cancer Center, proposed ideas for
manipulating the impact of variables such as distance on the
HSCT patient population included local physician education,
HSCT-speciﬁc outreach clinics, and telemedicine [4]. The
LTTC addresses these issues by providing a specialized clinic
with regularly scheduled follow-up, a robust telemedicine
system including telephone and Internet based correspon-
dence, and providing information packets and a physician of
contact for patients’ local providers. The proposed factors are
astutely noted in the Dana-Farber/Brigham and Women’s
Cancer Center study, and the focus of the LTTC on these
speciﬁc factors is presumed as a reason for the elimination of
distance as a factor in OS.
Instituting the long-term follow-up model will involve
the support and cooperation of the transplant center.
Transplant centers earn the designation of centers of
excellence based on a variety of factors, including certiﬁca-
tion by the Foundation for the Accreditation of Cellular
Therapy and facility, program, and outcome criteria that
vary with third-party payers. Both Foundation for the
Accreditation of Cellular Therapy and third-party payers
typically rely on a minimum number of transplants per year.
The assumption is that higher center volume predicts better
outcome, as has been shown in other organ transplants and
subsequently may be associated with less resource utiliza-
tion [13,14]. Although center volumemay be associated with
improved outcome, it accounts for a small proportion of
variability in mortality [15]. A recent study undertaken by
the Pediatric Blood and Marrow Transplant Consortium
could not ﬁnd an association between center volume and
day 100 mortality [16]. A review of transplant center factors
proposed to generate improved outcomes after HSCT will
allow better deﬁned criteria for designation as a center of
excellence.
Current criteria to obtain a center of excellence distinc-
tion for a stem cell transplant center across major payers
does not include long-term follow-up care models. Because
day 100 mortality rapidly approaches less than 10% at many
centers, a shift of focus is needed to posteday-100 follow-up,
a critical period when the patient transitions to his or her
home environment under the care of the referring
hematologist-oncologist and primary care physician. It is
imperative that healthcare delivery models, focusing on
well-integrated, multidisciplinary, posteday-100 follow-up
care, are developed to improve outcomes of HSCT. These
models should subsequently be considered as 1 criteria for
designation as a center of excellence or distinction.The retrospective nature of this study was a limitation of
this analysis. With the signiﬁcant amount of factors involved
with HSCT, it is very likely that several confounders were
unaccounted for in our analysis. Although a signiﬁcant
number of patients are represented in this study, increasing
the power by analyzing similar patients at other large
transplant centers with dedicated LTTCs may help to further
show that dedicated long-term care can overcome previ-
ously identiﬁed factors proposed to worsen OS. Following
HSCT patients prospectively with this long-term healthcare
model in place would allow us to analyze the exact impact of
this intervention on long-term survival after HSCT. Multi-
center comparative studies with different posteday-100
HSCT models are necessary to understand the optimal
healthcare delivery system. Obviously, there are many chal-
lenges to this type of study proposal, with time and power
the greatest limitations.
It is notable that patients whowere unable to transition to
the LTTC after HSCT may have had early relapse, graft failure,
or signiﬁcant transplant-related complications, including
mortality. Because this analysis was focused on long-term
follow-up care and its impact on outcomes, it is important
to remember that optimizing care immediately before
transplantation and in the critical 100 days after transplant
should remain a focus of investigators. As complications are
decreased in this critical time period, the focus can be shifted
to long-term follow-up care.
Systematic care in the LTTC to monitor, prevent, and treat
chronic GVHD and late effects after HSCT will be increasingly
important to optimize outcomes and should be considered
an integral part of a transplant program. Further investiga-
tion and implementation of this long-term follow-up
healthcare model is necessary as the population of long-term
survivors with signiﬁcant long-term health effects increases.
A recent review by Majhail and Rizzo [8] found the need for
further investigation into long-term follow-up models is
increasing as the focus shifts from the transplant period to
survivorship after day 100. With each improvement in
transplantation leading to improved rates of OS, there should
be similar progresses in the long-term follow-up care model
to provide survivors of transplantation enriched and
enduring outcomes after HSCT. The dedicated LTTC over-
comes previously recognized geographic barriers after HSCT
and helps to meet the increasing long-term healthcare needs
of HSCT survivors.
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